What is Epithelioid Mesothelioma?
Epithelioid mesothelioma is a form of cancer that develops in the mesothelial cells that line the body's cavities, including the lungs (pleura), abdomen (peritoneum), and heart (pericardium). The epithelioid cell type is the most common, representing approximately 50-70% of all mesothelioma diagnoses.
Why Cell Type Matters
The cell type of mesothelioma significantly influences:
- How the cancer grows and spreads
- Treatment options available
- Response to chemotherapy and radiation
- Overall prognosis and survival rates
- Life expectancy after diagnosis
Of the three main cell types—epithelioid, sarcomatoid, and biphasic—epithelioid has the slowest growth rate and responds best to treatment.
Development and Progression
Epithelioid mesothelioma develops when asbestos fibers become trapped in the mesothelium, triggering chronic inflammation and genetic mutations that transform normal mesothelial cells into cancerous epithelioid cells. These cells:
- Clump together in recognizable patterns
- Grow more slowly than sarcomatoid cells
- Are more responsive to standard cancer treatments
- Metastasize (spread) less aggressively
Epithelioid Cell Characteristics
Under microscopic examination, epithelioid cells have distinct characteristics that help pathologists identify them.
Morphology (Cell Structure)
- Shape: Cube-like or polygonal (boxy appearance)
- Nucleus: Visible, often centrally located
- Cytoplasm: Abundant, eosinophilic (pink-staining)
- Cell borders: Well-defined
- Arrangement: Form gland-like or tubular structures
Growth Patterns
Epithelioid cells typically arrange themselves in recognizable patterns including:
- Tubulopapillary (tube and finger-like projections)
- Acinar (gland-like)
- Adenomatoid (resembling adenomas)
- Solid sheets of cells
Behavior
Epithelioid cells behave differently from other mesothelioma cell types:
- Grow more slowly
- Remain more localized before spreading
- Stick together in cohesive groups
- More likely to respond to chemotherapy
- Better surgical candidates
Diagnosing Epithelioid Mesothelioma
Accurate diagnosis of epithelioid mesothelioma requires specialized pathology and immunohistochemistry staining.
Immunohistochemistry (IHC) Markers
Pathologists use specific antibodies to identify epithelioid mesothelioma. Understanding these immunohistochemistry findings is essential for accurate diagnosis:
Positive Markers (indicate mesothelioma):
- Calretinin: Highly sensitive for mesothelioma
- WT-1: Nuclear staining pattern
- Cytokeratin 5/6 (CK5/6): Strong expression
- Mesothelin: Cell surface protein
- D2-40: Lymphatic marker
Negative Markers (rule out other cancers):
- CEA (Carcinoembryonic Antigen): Negative in mesothelioma
- Ber-EP4: Negative in mesothelioma
- MOC-31: Negative in mesothelioma
- B72.3: Negative in mesothelioma
Differential Diagnosis
Epithelioid mesothelioma must be distinguished from:
- Adenocarcinoma of the lung
- Metastatic carcinoma
- Reactive mesothelial hyperplasia (non-cancerous)
- Other epithelioid tumors
Biopsy Requirements
Adequate tissue sampling is essential for accurate diagnosis:
- Surgical biopsy preferred over needle biopsy
- Multiple samples help ensure accuracy
- Review by pathologist experienced in mesothelioma. Detailed analysis in our pathology report guide
- Second opinion may be valuable
Histological Subtypes of Epithelioid Mesothelioma
Epithelioid mesothelioma includes several subtypes that pathologists may identify. These subtypes generally don't change treatment but may have slightly different prognostic implications.
Tubulopapillary
- Most common subtype
- Forms tube-like and finger-like structures
- Generally favorable prognosis
- Easy to distinguish from adenocarcinoma
Acinar/Adenomatoid
- Gland-like pattern
- May resemble lung adenocarcinoma
- Requires careful differential diagnosis
- Good response to treatment
Solid
- Sheets of cells without special pattern
- May be more aggressive than other subtypes
- Requires extensive IHC for diagnosis
Deciduoid
- Rare subtype
- Large cells with abundant cytoplasm
- More common in peritoneal mesothelioma
- May have more aggressive behavior
Well-Differentiated Papillary
- Relatively rare
- May behave less aggressively
- Slower growing variant
Treatment Options for Epithelioid Mesothelioma
Epithelioid mesothelioma responds better to treatment than other cell types, giving patients more options and better outcomes.
Surgery
Epithelioid cell type is more likely to be resectable (removable by surgery):
- Pleural mesothelioma: EPP or P/D procedures
- Peritoneal mesothelioma: CRS/HIPEC
- Complete macroscopic resection more achievable
- Better response when combined with other treatments
Chemotherapy
Epithelioid cells respond more favorably to chemotherapy:
- Pemetrexed + Cisplatin: Standard first-line with good response rates
- Response rate: 40-50% in epithelioid vs. 20-30% in sarcomatoid
- HIPEC: Excellent response for peritoneal cases
- Second-line options more likely to be effective
Radiation Therapy
- Adjuvant radiation after surgery
- Prophylactic radiation to surgical scars
- Palliative radiation for pain control
- Better tolerated than in sarcomatoid cases
Immunotherapy
Emerging data suggests epithelioid mesothelioma may respond better to immunotherapy:
- Pembrolizumab (Keytruda)
- Nivolumab + Ipilimumab combination
- Tumor marker testing can help predict immunotherapy response
- Clinical trials showing promise
Multimodal Treatment
Combining treatments often provides best outcomes:
- Surgery + HIPEC (for peritoneal)
- Surgery + Chemotherapy + Radiation (for pleural)
- Neoadjuvant and adjuvant chemotherapy
Prognosis and Survival Rates
Epithelioid mesothelioma has the best prognosis of all mesothelioma cell types, though outcomes still vary significantly based on stage and treatment.
Survival Statistics
| Factor | Epithelioid | Biphasic | Sarcomatoid |
|---|---|---|---|
| Median Survival | 12-24 months | 10-15 months | 6-12 months |
| 2-Year Survival | 30-45% | 15-25% | 5-10% |
| 5-Year Survival | 10-15% | 5% | <1% |
Factors Improving Prognosis
- Early stage: Stage 1-2 disease
- Surgical candidacy: Able to undergo resection
- Complete cytoreduction: All visible tumor removed
- Good performance status: Active and healthy
- Younger age: Better tolerance of treatment
- Female gender: Slightly better outcomes
- Peritoneal location: Better than pleural for this cell type
Long-Term Survivors
Some epithelioid mesothelioma patients become long-term survivors:
- 5-10+ year survival is possible
- Mostly early-stage patients with aggressive treatment
- Complete response to CRS/HIPEC for peritoneal cases
- Ongoing research into factors predicting long survival
Comparing Mesothelioma Cell Types
Understanding how epithelioid mesothelioma differs from other cell types helps patients understand their diagnosis.
Epithelioid vs. Sarcomatoid
| Characteristic | Epithelioid | Sarcomatoid |
|---|---|---|
| Cell shape | Cube-like, defined | Spindle-shaped |
| Growth rate | Slower | Faster |
| Metastasis | Less aggressive | Highly aggressive |
| Treatment response | Good | Poor |
| Surgery benefit | High | Limited |
Epithelioid vs. Biphasic
Biphasic mesothelioma contains both epithelioid and sarcomatoid cells. The prognosis depends on the ratio:
- Higher epithelioid component = better prognosis
- Higher sarcomatoid component = poorer prognosis
- Treatment decisions based on dominant cell type
Frequently Asked Questions
Is epithelioid mesothelioma curable?
While epithelioid mesothelioma is rarely considered "cured," some patients achieve long-term remission, particularly with aggressive multimodal treatment. Five to ten-year survival is possible, especially for early-stage peritoneal mesothelioma treated with CRS/HIPEC. Treatment aims to control the disease and extend life.
Can the cell type change over time?
The primary cell type generally remains consistent, though tumors may develop mixed features over time. If cancer recurs after treatment, the pathology should be re-reviewed as the cell type characteristics may have changed. This is why biopsies of recurrent disease are important.
How is epithelioid mesothelioma definitively diagnosed?
Definitive diagnosis requires tissue biopsy examined by a pathologist experienced in mesothelioma. Immunohistochemistry staining with specific markers (calretinin, WT-1, cytokeratin 5/6 positive; CEA, Ber-EP4 negative) helps distinguish epithelioid mesothelioma from adenocarcinoma and other similar cancers.
Does epithelioid mesothelioma always have a better prognosis?
While epithelioid cell type is generally associated with better outcomes, prognosis still depends heavily on stage at diagnosis, tumor location, patient health, and treatment received. Late-stage epithelioid mesothelioma still carries a serious prognosis, though typically better than equivalent-stage sarcomatoid disease.
Are clinical trials available specifically for epithelioid mesothelioma?
Many clinical trials accept patients regardless of cell type, but some studies specifically target epithelioid mesothelioma or exclude sarcomatoid cases due to different biology and treatment response. Your oncologist can help identify trials appropriate for your specific cell type and situation.
Should I get a second opinion on my cell type diagnosis?
Yes, second opinions on pathology are valuable for mesothelioma due to its rarity and diagnostic complexity. Misclassification between cell types occurs and can significantly impact treatment decisions. Major cancer centers and specialized mesothelioma programs can provide expert pathology review.
Understand Your Cell Type
If you've been diagnosed with epithelioid mesothelioma, connect with specialists who understand the unique treatment approaches for this cell type.
Find Specialists